Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Urogen Pharma Ltd (NQ: URGN )

14.27 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 14.27
Bid (Size) 5.710 (2)
Ask (Size) 18.39 (1)
Prev. Close 14.27
Today's Range 14.27 - 14.27
52wk Range 10.60 - 20.70
Shares Outstanding 36,130,121
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q2 2024
URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
-6.18%
-6.18%
1 Month
-11.59%
-11.59%
3 Month
+4.85%
+4.85%
6 Month
-23.24%
-23.24%
1 Year
-21.94%
-21.94%

More News

Read More
UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
From UroGen Pharma Ltd.
Via Business Wire
UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug
Via Investor's Business Daily
UroGen Pharma Stock Earns 91 RS Rating
Via Investor's Business Daily
NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
From UroGen Pharma Ltd.
Via Business Wire
Hasbro, Tutor Perini, Arm Holdings And Other Big Stocks Moving Higher On Friday
Via Benzinga
Hasbro To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
From UroGen Pharma Ltd.
Via Business Wire
URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Participate at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
From UroGen Pharma Ltd.
Via Business Wire
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
From UroGen Pharma Ltd.
Via Business Wire
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
From UroGen Pharma Ltd.
Via Business Wire
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
From UroGen Pharma Ltd.
Via Business Wire
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.